We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Developed for Legionnaires' Disease

By LabMedica International staff writers
Posted on 29 Sep 2011
Print article
Separate measurement of antibodies to Legionella pneumophila serogroups as single antigens can facilitate an early diagnosis of Legionnaires' disease.

An enzyme-linked immunosorbent assay (ELISA) was developed and evaluated to determine whether separate measurement of immunoglobulin (Ig) M and G antibodies to L. pneumophila serogroups 1, 3 and 6 as single antigens can assist in the diagnosis.

Scientists at the Statens Serum Institut (Copenhagen, Denmark) compared the ELISA with an in-house indirect Legionella immunofluorescence antibody test (IFAT) measuring Total Ig. A total of 193 sera from 128 patients with confirmed L. pneumophila infections were used to assess the sensitivity of the developed ELISA. The sensitivity was assessed in different time-periods after onset of symptoms. L. pneumoniae infection was confirmed by one or more of the following methods: culture by standard method, Legionella urinary antigen EIA (Biotest AG, Dreieich, Germany), and an in-house polymerase chain reaction (PCR) method.

It was found that the sensitivity of the ELISA increased during the first month of infection, IgM being the most sensitive; ranging from 13% in the first week after onset of symptoms, 45% in the second week to 84% in the third week; in the fourth week and beyond, a drop to 67% was discerned. The IFAT detecting L. pneumophila subgroups 1–6 had a sensitivity of 11%, 27%, 80%, and 59%, respectively, during these time-periods. The test with the lowest sensitivity during these time-periods was the IgG ELISA (0%, 21%, 36%, and 52%) respectively, but by combining the IgG results with the IgM results, the overall sensitivity of the assay was improved (13%, 48%, 88%, and 70%), respectively.

The in-house methods IgM ELISA and IFAT both had a low false positive rate: 7% and 4% among 75 samples. In contrast, the IgG ELISA had a false positive rate of 14%, which was high compared to the other tests. The sera which were positive for Helicobacter pylori, Salmonella typhimurium/enteritidis, and Mycoplasma pneumoniae showed the highest rate of false positive in the IgG subgroup1 ELISA. The sera, which caused the false positive results in the IFAT and IgM ELISA were the sera with antibodies to Proteus species and S. typhimurium/enteritidis.

The study confirmed that detection of IgG and IgM antibodies by ELISA is an important diagnostic tool especially during the initial phase of the disease, when supported by other tests like the urinary antigen test, PCR, or culture of the organism. The authors concluded that specific antibodies against L. pneumophila subgroups 1, 3, and 6 can be detected in patients early in the course of infection. Furthermore, positive IgM level can be used as a good indicator of an ongoing or recent Legionella infection. The study was published in September 2011, in the Journal of Microbiological Methods.

Related Links:
Statens Serum Institut
Biotest AG


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.